These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 25581761)
21. A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-Kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer. Russo GI; Regis F; Castelli T; Favilla V; Privitera S; Giardina R; Cimino S; Morgia G Clin Genitourin Cancer; 2017 Aug; 15(4):429-439.e1. PubMed ID: 28111174 [TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022 [TBL] [Abstract][Full Text] [Related]
23. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening. McDonald ML; Parsons JK Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027 [TBL] [Abstract][Full Text] [Related]
24. Advances in biomarkers for the early diagnosis of prostate cancer. Cao DL; Yao XD Chin J Cancer; 2010 Feb; 29(2):229-33. PubMed ID: 20109357 [TBL] [Abstract][Full Text] [Related]
25. Prognostic and predictive biomarkers in prostate cancer. Kontos CK; Adamopoulos PG; Scorilas A Expert Rev Mol Diagn; 2015; 15(12):1567-76. PubMed ID: 26548550 [TBL] [Abstract][Full Text] [Related]
26. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Foj L; Milà M; Mengual L; Luque P; Alcaraz A; Jiménez W; Filella X Clin Chim Acta; 2014 Aug; 435():53-8. PubMed ID: 24803095 [TBL] [Abstract][Full Text] [Related]
27. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239 [TBL] [Abstract][Full Text] [Related]
28. From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma. Zhang MZ; Lu YP Chin Med J (Engl); 2012 May; 125(9):1643-9. PubMed ID: 22800836 [TBL] [Abstract][Full Text] [Related]
29. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer. Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666 [TBL] [Abstract][Full Text] [Related]
30. PCA3 in the detection and management of early prostate cancer. Filella X; Foj L; Milà M; Augé JM; Molina R; Jiménez W Tumour Biol; 2013 Jun; 34(3):1337-47. PubMed ID: 23504524 [TBL] [Abstract][Full Text] [Related]
31. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis. Luo Y; Gou X; Huang P; Mou C Chin Med J (Engl); 2014; 127(9):1768-74. PubMed ID: 24791889 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828 [TBL] [Abstract][Full Text] [Related]
33. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487 [TBL] [Abstract][Full Text] [Related]
34. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565 [TBL] [Abstract][Full Text] [Related]
35. Kallikreins as biomarkers for prostate cancer. Hong SK Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052 [TBL] [Abstract][Full Text] [Related]
36. [The level of evidence for the use of biomarkers in the early detection of prostate cancer]. Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X; Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727 [TBL] [Abstract][Full Text] [Related]
37. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154 [TBL] [Abstract][Full Text] [Related]
38. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy. Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170 [TBL] [Abstract][Full Text] [Related]
39. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594 [TBL] [Abstract][Full Text] [Related]
40. A novel algorithm for the prediction of prostate cancer in clinically suspected patients. Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]